Cargando…
Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study
OBJECTIVES: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole. METHODS: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020. RESULTS: Patients had a mean age of 40.6±14.2 years...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fujita Medical Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405899/ https://www.ncbi.nlm.nih.gov/pubmed/37554938 http://dx.doi.org/10.20407/fmj.2022-031 |
_version_ | 1785085636648108032 |
---|---|
author | Yokoi, Rina Hatano, Masakazu Kamei, Hiroyuki Morita, Aoi Hanya, Manako Iwata, Nakao Yamada, Shigeki |
author_facet | Yokoi, Rina Hatano, Masakazu Kamei, Hiroyuki Morita, Aoi Hanya, Manako Iwata, Nakao Yamada, Shigeki |
author_sort | Yokoi, Rina |
collection | PubMed |
description | OBJECTIVES: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole. METHODS: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020. RESULTS: Patients had a mean age of 40.6±14.2 years and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4.6±1.2 at the initiation of brexpiprazole treatment. The Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) total score significantly improved from 68.1±22.3 in week 2 to 79.5±21.0 in week 14 (p=0.0084). The SWNS-J subscales of self-control and social integration status also significantly improved from 14.0±4.7 and 13.9±6.0 in week 2 to 17.0±4.7 and 16.0±5.1 in week 14, respectively (p=0.0053 and 0.012, respectively). No significant improvements were observed in any other SWNS-J subscales or the Drug Attitude Inventory-10 (DAI-10) in the 14-week observation period. Moreover, the SWNS-J total score did not correlate with the DAI-10 (r=0.31, p=0.19), or CGI-S (r=–0.18, p=0.47) scores. CONCLUSIONS: The present results suggest that brexpiprazole might improve subjective well-being, although this may not necessarily reflect psychopathological improvements. To enhance medication adherence, it is important to perform subjective assessments on patients over time. |
format | Online Article Text |
id | pubmed-10405899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Fujita Medical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-104058992023-08-08 Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study Yokoi, Rina Hatano, Masakazu Kamei, Hiroyuki Morita, Aoi Hanya, Manako Iwata, Nakao Yamada, Shigeki Fujita Med J Original Article OBJECTIVES: To investigate the subjective assessments of an antipsychotic treatment with brexpiprazole. METHODS: This was a 14-week prospective observational study. Nineteen patients participated in the study between February 2019 and January 2020. RESULTS: Patients had a mean age of 40.6±14.2 years and a Clinical Global Impressions-Severity of Illness scale (CGI-S) score of 4.6±1.2 at the initiation of brexpiprazole treatment. The Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J) total score significantly improved from 68.1±22.3 in week 2 to 79.5±21.0 in week 14 (p=0.0084). The SWNS-J subscales of self-control and social integration status also significantly improved from 14.0±4.7 and 13.9±6.0 in week 2 to 17.0±4.7 and 16.0±5.1 in week 14, respectively (p=0.0053 and 0.012, respectively). No significant improvements were observed in any other SWNS-J subscales or the Drug Attitude Inventory-10 (DAI-10) in the 14-week observation period. Moreover, the SWNS-J total score did not correlate with the DAI-10 (r=0.31, p=0.19), or CGI-S (r=–0.18, p=0.47) scores. CONCLUSIONS: The present results suggest that brexpiprazole might improve subjective well-being, although this may not necessarily reflect psychopathological improvements. To enhance medication adherence, it is important to perform subjective assessments on patients over time. Fujita Medical Society 2023-08 2023-05-09 /pmc/articles/PMC10405899/ /pubmed/37554938 http://dx.doi.org/10.20407/fmj.2022-031 Text en https://creativecommons.org/licenses/by/4.0/This is an Open access article distributed under the Terms of Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Article Yokoi, Rina Hatano, Masakazu Kamei, Hiroyuki Morita, Aoi Hanya, Manako Iwata, Nakao Yamada, Shigeki Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title_full | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title_fullStr | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title_full_unstemmed | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title_short | Subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
title_sort | subjective assessment of brexpiprazole in patients with schizophrenia: a prospective observational study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405899/ https://www.ncbi.nlm.nih.gov/pubmed/37554938 http://dx.doi.org/10.20407/fmj.2022-031 |
work_keys_str_mv | AT yokoirina subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT hatanomasakazu subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT kameihiroyuki subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT moritaaoi subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT hanyamanako subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT iwatanakao subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy AT yamadashigeki subjectiveassessmentofbrexpiprazoleinpatientswithschizophreniaaprospectiveobservationalstudy |